Clinical Trial Detail

NCT ID NCT02450331
Title A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (IMvigor010)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

bladder urothelial carcinoma

Therapies

Atezolizumab

Age Groups: adult senior

No variant requirements are available.